It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
Executive Summary
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
You may also be interested in...
Syngene Eyes Sweet Spot As New Modalities Hog Limelight
Syngene’s CEO discusses its work in ADC development and trends in the CRDMO space as US biotechs navigate a funding squeeze and manufacturing opportunities loom in areas like GLP- 1 receptor agonists.
Japan Q3 Roundup: Majors Enjoy Forex Windfall But COVID Returns Decline
While the weaker yen boosted the top line for Japanese pharma companies with a strong global presence in the fiscal first half, it also raised reported costs. Several firms reported strong growth for mainstays, while holding out high hopes for selected new drugs with blockbuster potential. But some other products underperformed for unexpected reasons.
BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.